Foundation for Global Skin Health Strategies

Co-Founders

Board
of Directors

Scientific
Advisory Board

Business
Advisory Board

Foundation Board members meeting at Harvard Club in New York.

John G. Callahan (left) and William M. Noé attend presentation on advances in the treatment of Melanoma.

Related
Resources

  • American Academy
    of Dermatology
  • American Contact Dermatitis Society
  • The American Society for Clinical Investigation
  • Biopelle
  • Ferndale Laboratories Inc.

Board of Directors

William Levis, M.D.

Dr. Levis is Chairman of the Foundation. In his early career he held several positions with the National Cancer Institutes culminating in an appointment as Senior Investigator, Dermatology Branch. He then served for a period as the Chief of the department of Dermatology at US Public Health Service in Staten Island. Dr. Levis went on to serve as Medical Specialist at the New York State Institute for Basic Research in Developmental Disabilities and has held the positions of Adjunct Professor of Dermatology, New York Medical College and Adjunct Professor of Medicine, Cornell University Medical College. He is world renowned for his work in Hansen's disease and is credited with bringing it under global control. Dr. Levis has served as Director, New York Hansen's Disease Program and Attending Physician Staten Island University Hospital, Staten Island, NY. He is presently Attending Physician, New York Hansen’s Disease Program, Bellevue Hospital Center, New York, NY. In 2008, he opened the Levis Dermatology private practice in New York City.

Dr. Levis has published extensively and has presented many lectures
at international venues. In 2008 he was honored with internationally prestigious Astellas Award for Public Health.

Dr. Levis is a member of the American Society of Clinical Investigation,
an honor society of physician-scientists whose mission is to translate discoveries in the laboratory into valuable and practical advances in
clinical medicine. Founded in 1908, the Society is a forum for more than 2,800 luminaries and pioneers of academic medicine and industrial healthcare. Dr. Levis is today engaged in the research and clinical development of new immunomodulator technologies for the treatment of dermatological viral diseases, melanoma and for the diagnosis and treatment of immunomodulator responsive AIDS patients.

Michael Burns, Ph.D.

Dr. Burns is the President and Chief Operating Officer of Michigan based Ferndale Pharma Group, Inc. and Chief Executive Officer of its Ferndale Laboratories, Eloquest Healthcare and Biopelle subsidiaries. For over 15 years Dr. Burns has held several executive positions at Ferndale Pharma Group which develops, manufactures and markets a variety of prescription and non-prescription dermatological and related products. With over 30 years in the international pharmaceutical and health care industries, Dr. Burns has extensive senior and general management experience in FDA regulated manufacturing and laboratory operations, research and development, corporate and business development, licensing, acquisitions, sales and marketing.

Prior to his recent return to Ferndale Dr. Burns was Chief Executive Officer of Repromedix Corp., a Massachusetts based company specializing in the diagnosis of male and female infertility. He is a co-founder and presently serves as Vice President of Corporate Development at ReproSource Inc which markets multivariate diagnostic tests that improve live birth rates in couples with infertility. He has played a leading role in establishing a joint venture for sale and marketing of these diagnostic tests in China. Dr. Burns is also on the boards of business and scientific advisor to SciTech LLC, a Michigan based enterprise that performs translation research and development. SciTech is actively developing new drugs for solid tumors, non-melanoma skin cancers and pre-cancers.

Dr. Burns, a native of Britain and Germany, has a B.Sc. Honors degree from the University of Reading in Physiology, Biochemistry & Chemistry, an M.B.A. in Marketing and Strategic Planning from Loughborough University of Science and Technology and obtained his Ph.D. in Pharmacology from the Universities of Cambridge and Nottingham.

Georgia Schuller Levis, Ph.D.

Dr. Georgia Schuller-Levis specialized in the disciplines of Pharmacology and Microbiology. After two years of undergraduate research in the pharmaceutical industry she completed her graduate studies and obtained her Ph.D. from the Medical College of Virginia, Richmond where she then served as Assistant Professor of Microbiology before advancing take a position at the Food and Drug Administration.

Since 1981 Dr. Schuller-Levis pioneered key research in the field of cellular immunology at the Neuroscience Research Institute of the New York State Institute for Basic Research in Developmental Disabilities, Staten Island. She is widely published worldwide and is a highly regarded expert and opinion leader on the pharmacology, immunology and cellular biology of the sulfur containing amino acid taurine. She and her Institute are credited with recognition of the crucial role that taurine plays in the neurological development of newborns and infants – an endeavor that led to the routine incorporation of taurine as a nutritional supplement in infant formulae. Dr Schuller-Levis was a member of the New York Academy of Science, the American Society for Microbiologists, the Society for Leukocyte Biology, the American Association of Immunologists, the American Institute of Nutrition and the International Cytokine Society.

Brian Charles Keller, PhD

Dr. Brian Keller is Co-Founder of BioZone Laboratories, Inc. where he currently serves as its Executive Vice President. Based near San Francisco, California, BioZone specializes in research, development and manufacturing of nano-encapsulation of drug products. Dr. Keller is an internationally recognized lecturer and consultant on pharmaceuticals and drug delivery. He is a leading expert on the science of liposomes and nano-vesicles. He has been awarded seven patents for his work with liposomal drug delivery and inflammation. Prior to forming BioZone, Dr. Keller was Clinical Pharmacologist at St. Luke's Hospital, San Francisco. Dr. Keller's memberships include: fellow of the American College of Nutrition, member of the American Association of Pharmaceutical Scientists, the American Association for the Advancement of Science, the American Chemical Society and the American Oil Chemists Society.

Daniel Fisher

Mr. Fisher Secretary of the Foundation and Co-Founding President of BioZone Laboratories, Inc. BioZone is a leading developer of drug delivery technologies. It also develops and contract manufactures personal care products and pharmaceutical drugs. Prior to co-founding BioZone in 1989, his experience base of more than twenty years includes senior sales and marketing management of consumer and technical product companies, including Dun & Bradstreet, General Foods Corporation and Control Data Corporation.